Haarlem, Netherlands

Cornelis Johannes Melief


 

Average Co-Inventor Count = 2.8

ph-index = 3

Forward Citations = 22(Granted Patents)


Company Filing History:


Years Active: 1998-2017

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Cornelis Johannes Melief: Innovator in HPV Research

Introduction

Cornelis Johannes Melief is a notable inventor based in Haarlem, Netherlands. He has made significant contributions to the field of medical research, particularly in the development of vaccines targeting HPV-related diseases. With a total of three patents to his name, Melief's work has the potential to impact cancer treatment and prevention.

Latest Patents

One of Melief's latest patents is focused on HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines. This invention relates to novel CD4+ and CD8+ T cell epitopes that are specific for HPV-specific E6 and E7 oncoproteins. The patent includes peptides comprising these novel T cell epitopes and compositions for their use in preventing and treating HPV-related diseases. Preferred epitopes are recognized by T cells that infiltrate cervical neoplastic lesions or by T cells from draining lymph nodes, presented by HLA-DQ, HLA-DP, or HLA-B molecules.

Another significant patent involves PRAME derived peptides and immunogenic compositions. This invention describes a peptide with a length of no more than 100 amino acids, which includes at least 19 contiguous amino acids from the human PRAME protein. The peptide comprises at least one HLA class II epitope and one HLA class I epitope, and it is intended for use as a medicament for cancer treatment and prevention.

Career Highlights

Throughout his career, Melief has worked with esteemed institutions such as Leiden University and Seed Capital Investments B.V. His research has been pivotal in advancing the understanding of immune responses to cancer, particularly in relation to HPV.

Collaborations

Melief has collaborated with notable colleagues, including Wybe Martin Kast and Jan Kessler. Their joint efforts have contributed to the development of innovative solutions in the field of immunology and cancer research.

Conclusion

Cornelis Johannes Melief's work exemplifies the intersection of innovation and medical research. His patents and collaborations highlight his commitment to advancing cancer treatment through targeted immunotherapy.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…